November 2012

Sanofi would like to assure you that this out-of-stock situation of Sofradex® is temporary and at present, we are actively and earnestly endeavouring to make sure that we will have stock of Sofradex® 8ml available as soon as possible to prevent any further disruption and inconvenience. Should you have any further queries, please contact our […]

Seroquel XR 150mg® is now launched and is indicated as adjunctive therapy in the treatment of resistant major depressive disorder. It should be administered once daily in the evening, with or without food, and swallowed whole and not split, chewed or crushed. The initial dose for major depressive disorder should begin at 50mg on Day

It contains dry ivy leaf extract (Hedera Helix) that has expectorant and spasmolytic actions. It is indicated for: Acute inflammation of the respiratory tract and for the improvement of symptoms of chronic-inflammatory bronchial disease. SEP price incl VAT is R45.00

MSD has launched of JANUVIA® (25 mg, 50 mg, 100 mg daily), a new oral antidiabetic agent for the treatment of type 2 diabetes. JANUVIA® contains sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor (incretin enhancer) that increases the levels of two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones play a

Novartis South Africa is pleased to announce the introduction of Galvus®Met effective from 17 October 2012. This is in addition to the Galvus® range, enhancing their metabolic portfolio. Here are the Galvus®Met options: Galvus Met 50mg/850mg tablets in 30’s and 60’s Galvus Met 50mg/1000mg tablets in 30’s and 60’s

Astellas Pharma has discontinued the 100g pack size of Locoid Crelo. However, the Locoid Crelo 30g pack size is still available.

n a concerted effort to ensure excellence and the successful implementation of the goals set in the Human Resources for Health Strategy, the Minister of Health, Dr Aaron Motsoaledi will on Tuesday, 6 November launch the Academy for Leadership and Management in Health Care to address skills gaps at all levels, including clinical and hospital

Launch of Co-Exforge – Novartis South Africa has launched Co-Exforge® effective from 23 October 2012. It includes: Co-Exforge® 5 mg/160 mg/12,5 mg Co-Exforge® 5 mg/160 mg/25 mg Co-Exforge® 10 mg/160 mg/12,5 mg Co-Exforge® 10 mg/160 mg/25 mg For any queries please contact the Novartis Customer Support Line on 0861 929 929